First-in-human evaluation of 225Ac-PSMA-Trillium™ (BAY 3563254; 225Ac felivotide mopaxetan) in metastatic castration-resistant prostate cancer: the phase 1 PAnTHA study
The phase 1 PAnTHA study demonstrates that the alpha-emitting radioligand [225Ac]Ac-PSMA-Trillium exhibits a manageable safety profile and strong preliminary efficacy, including a 62% PSA50 response rate, in heavily pretreated patients with metastatic castration-resistant prostate cancer.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For men with advanced prostate cancer that no longer responds to hormone therapy, the medical landscape has long been defined by a difficult progression. Standard treatments, including chemotherapy and newer hormone-blocking drugs, often lose their effectiveness over time, leaving patients with few options and a life expectancy measured in months. In recent years, a new approach has emerged that targets the cancer cells directly using radiation delivered by a tiny molecule. This method, known as targeted radioligand therapy, works by attaching a radioactive particle to a substance that seeks out a specific protein found on the surface of prostate cancer cells. Once attached, the radiation destroys the cell from the inside. While a version of this treatment using a beta-emitting particle has shown success, scientists have been exploring whether a different type of radiation, one that is far more powerful but travels a much shorter distance, could be even more effective. This more potent radiation comes from a rare isotope called actinium-225, which acts like a microscopic sniper, delivering a lethal dose of energy to the cancer cell while sparing the surrounding healthy tissue.
A team of researchers recently conducted the first study in humans to test a new drug designed to harness this powerful radiation for treating metastatic prostate cancer. The drug, known as 225Ac-PSMA-Trillium, combines the actinium-225 isotope with a molecule that specifically hunts down prostate cancer cells. The study, involving fifty patients whose cancer had spread and who had already tried multiple other treatments, aimed to see if the drug was safe to use and if it could shrink tumors. The researchers administered the drug intravenously in cycles, gradually increasing the amount of radiation given to different groups of patients to find the optimal dose. They monitored the patients closely for any signs of harm, paying particular attention to side effects that had caused problems with similar drugs in the past, such as dry mouth and damage to the blood cells.
The results of this initial trial were encouraging. The drug proved to be manageable, with no patients experiencing the severe, life-limiting toxicities that would have stopped the study. The most common side effect was dry mouth, which occurred in the vast majority of patients, but in almost all cases, it was mild to moderate and did not force anyone to stop treatment. While some patients experienced a drop in their white blood cell count or developed anemia, these issues were generally temporary and resolved with time or standard medical care. Crucially, the treatment showed strong signs of working. More than half of the patients saw their prostate-specific antigen levels, a key marker of cancer activity, drop by at least half. Among those whose cancer could be measured on scans, half achieved a partial response, meaning their tumors visibly shrank. The researchers found that patients whose cancer cells showed high levels of the target protein on imaging scans tended to have the deepest responses to the treatment.
Based on these findings, the team identified a specific dose that balanced safety with effectiveness for future testing. They observed that the drug was able to control the disease for a significant period in many patients, with some maintaining a response for nearly nine months. The study also highlighted that the drug's ability to bind to the cancer cells was linked to how well it worked, suggesting that the targeting mechanism was functioning as intended. While the study was small and focused on safety and early signs of efficacy, the data provided a clear path forward. The researchers concluded that this new approach, which delivers a highly potent form of radiation directly to the cancer, is a viable option for patients who have run out of other treatments. The work sets the stage for larger studies to confirm these early results and determine exactly how this powerful tool can best be used to extend and improve the lives of men with advanced prostate cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.